GTBP - GT Biopharma gives enrollment update in early-stage bone cancer study

GT Biopharma (GTBP) announces the enrollment of Patient 10 in its GTB-3550 TriKE first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes ((MDS)) and refractory/relapsed acute myeloid leukemia ((AML)) forms of bone marrow cancers.Up to 63.7% Reduction in Bone Marrow Blast Levels were observed in the first 9 patients in the study. The Patient 10 will be dosed at 100mcg/kg/day.The company also highlighted that no Progenitor-derived or Autologous/Allogenic cell therapy was required."The data from the first nine patients treated with GTB-3550 indicates significant bone marrow blast level reductions in AML and MDS patients without the need for expensive progenitor-derived or autologous/allogenic cell therapies," CEO Anthony Cataldo said.Shares up marginally during premarket trading.

For further details see:

GT Biopharma gives enrollment update in early-stage bone cancer study